Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Timeline

Start

2021-12-14

Primary completion

2024-11-04

Completion

2024-12-03

Drugs

Indications